title: Infliximab-induced discoid lupus erythematosus.
abstract: Anti-tumor necrosis factor-alpha (TNF-α) immunotherapy is currently used in the treatment of various inflammatory diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. Infliximab is a chimeric monoclonal antibody that binds to transmembrane-bound and soluble TNF-α. Previously, a discoid lupus erythematosus-like eruption linked to its use was rarely reported in patients with rheumatoid arthritis. We present a case of rheumatoid arthritis which developed such an eruption after treatment with infliximab. The lesions resolved after the discontinuation of infliximab. In the present case, the clinical, serological and immunohistochemical features of our patient are discussed with the literature.
authors.affiliation: Department of Dermatology, Ministry of Health Diskapi Yildirim Beyazit Education and Research Hospital, Turkey. dbcemil@yahoo.com
authors.forename: B C
authors.initials: BC
authors.lastname: Cemil
authors.forename: H
authors.initials: H
authors.lastname: Atas
authors.forename: F
authors.initials: F
authors.lastname: Canpolat
authors.forename: Y
authors.initials: Y
authors.lastname: Akca
authors.forename: R
authors.initials: R
authors.lastname: Sasmaz
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008179:Lupus Erythematosus, Discoid / Q000139:chemically induced*; D008297:Male; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab